Investors
Building the intelligence infrastructure for proactive public health.
We welcome conversations with investors who share our conviction that better intelligence - connected to action - can transform how the world protects populations.
Investment thesis
Why this, why now
AI public health infrastructure
Public health agencies and programmes need a connective intelligence layer between data systems and field action. We believe this is an infrastructure-scale need, not a point solution.
Recurring enterprise software
The intended model is recurring platform subscriptions for governments, NGOs, life sciences and healthcare networks, complemented by pilot partnerships and intelligence services.
High-burden disease applications
Starting with malaria and dengue - climate-sensitive diseases with large, persistent burdens and established intervention programmes that benefit from better targeting.
Global scalability
Shared methods and modules are designed to extend across geographies and diseases, with local partners and validation in each new setting.
Software and data defensibility
Defensibility is intended to come from integrated workflows, harmonized multi-source data pipelines, validated models and long-term programme relationships.
Diverse customer segments
Governments, NGOs, life sciences, healthcare networks, research institutions and philanthropies share the need - but buy for different reasons, broadening the opportunity.
Market opportunity and product vision
From fragmented tools to an intelligence layer
Public health organizations increasingly have access to surveillance, climate and programme data, yet often lack integrated tools that turn that data into timely, targeted and accountable action. Climate change, urbanization and constrained budgets are increasing the value of anticipation and precise targeting.
Epinova’s product vision spans the full cycle - Signal, Predict, Prioritize, Action, Connect and Impact - so customers can start with one need and expand across the platform over time.
Initial commercial strategy
Focused entry, deliberate expansion
- 01
Focus
Malaria in Nigeria and dengue in Maharashtra, India, as pilot-development priorities.
- 02
Prove
Co-designed pilots with pre-agreed evaluation criteria and partner-approved results.
- 03
Convert
Transition successful pilots to recurring platform subscriptions.
- 04
Expand
Additional geographies, diseases and customer segments.
This page describes strategy and intent. It is not an offer of securities, and Epinova does not publish fundraising terms, valuations or financial metrics on this website.
Investor enquiries
Start a conversation
Qualified investors are welcome to get in touch. We will respond personally and can share further materials under appropriate confidentiality.